Jian Jin, PhD
img_Jian Jin
PROFESSOR | Pharmacological Sciences
PROFESSOR | Oncological Sciences
PROFESSOR | Neuroscience
Research Topics
Cancer, Chromatin, Drug Design and Discovery, Epigenetics, Membrane Proteins/Channels, Neuroscience, Protein Degradation, Structural Biology
Multi-Disciplinary Training Area
Cancer Biology [CAB], Disease Mechanisms and Therapeutics (DMT)
Discovery of Novel Degraders Targeting Oncogenic Proteins
The Jin lab is a leader in developing novel degraders targeting oncogenic proteins. Since 2014, the lab has discovered and characterized a number of first-in-class degraders using the PROTAC (proteolysis targeting chimera) and hydrophobic tagging technologies. Our degrader program has resulted in multiple patent applications filed by Mount Sinai.
Discovery of Biased Ligands for G Protein-coupled Receptors
G protein-coupled receptors (GPCRs) signal not only via canonical pathways involving heterotrimeric large G proteins, but also via non-canonical G protein-independent interactions with other signaling proteins including beta-arrestins. Biased ligands of GPCRs preferentially engage either canonical or non-canonical signaling pathways and are extremely useful tools for elucidating the signal transduction pathways essential for both therapeutic actions and side-effects. The Jin lab has been actively engaged in discovering biased ligands of GPCRs for more than a decade.
Discovery of Selective Inhibitors for Histone Methyltransferases
Histone methyltransferases (HMTs, also known as protein methyltransferases (PMTs)) play critical roles in various human diseases including cancer. The Jin lab has taken a systematic approach to target HMTs for over a decade. By targeting the HMT substrate binding groove, cofactor binding site, and allosteric binding sites, the Jin lab has discovered numerous high quality selective inhibitors of HMTs, which have been widely used by the scientific community.

BS, University of Science and Technology of China

PhD, Pennsylvania State University

Postdoc, Ohio State University

Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device and biotechnology companies to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their relationships with such companies.

Below are financial relationships with industry reported by Dr. Jin during 2022 and/or 2023. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.


  • Accent Therapeutics, Inc.
  • Cullgen, Inc.
  • EpiCypher, Inc.

Equity (Stock or stock options valued at greater than 5% ownership of a publicly traded company or equity of any value in a privately held company)

  • Cullgen, Inc.

Royalty Payments:

  • LEVO
  • Cullgen
  • KinoDyn Inc. 
  • Cullgen, Inc.
  • Cullinan Oncology

Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.